BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 9120290)

  • 1. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
    J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
    Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
    Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
    J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W; Fong C
    Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
    J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-recognition of a mouse H-2-peptide complex by human HLA-restricted cytotoxic T cells.
    Murray RJ; Brooks JM; Rickinson AB; Rowe M
    Eur J Immunol; 1990 Mar; 20(3):659-64. PubMed ID: 1690661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan.
    Lin HJ; Cherng JM; Hung MS; Sayion Y; Lin JC
    J Biomed Sci; 2005 Dec; 12(6):925-36. PubMed ID: 16307312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population.
    Lee SP; Morgan S; Skinner J; Thomas WA; Jones SR; Sutton J; Khanna R; Whittle HC; Rickinson AB
    Eur J Immunol; 1995 Jan; 25(1):102-10. PubMed ID: 7531142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.
    Solache A; Morgan CL; Dodi AI; Morte C; Scott I; Baboonian C; Zal B; Goldman J; Grundy JE; Madrigal JA
    J Immunol; 1999 Nov; 163(10):5512-8. PubMed ID: 10553078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.